Clinical Trial Update: Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is investigating chimeric antigen receptor natural killer (CAR-NK) cell therapy for high-risk lymphoma in patients with Primary Sjögr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Sjögren Syndrome

Drugs mentioned

• Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapy (CAR-NK cell therapy)

Snippet

Sponsor: Bangdong Gong | Conditions: Primary Sjogren's Syndrome, Lymphoma | Phase 1, Phase 2 | Status: RECRUITING